TSFLAB04a:	Subjects With [Last/Any] On-treatment Chemistry Values [= Level 2] Criteria; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
Laboratory Category 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  Laboratory Test ≥ Level 2, n (%) 	N=53 	N=73 	N=59 	  	  	
General chemistry 	 	 	 	 	 	
Calcium, low (<1.996 mmol/L) 	46/53 (86.8%) 	53/68 (77.9%) 	55/58 (94.8%) 	-8.0 (-18.8, 2.7) 	-16.9 (-28.3, -5.5) 	
Glucose, low (<3.00 mmol/L) 	44/53 (83.0%) 	51/70 (72.9%) 	56/59 (94.9%) 	-11.9 (-23.5, -0.3) 	-22.1 (-33.9, -10.2) 	
Glucose, high (fasting ≥6.99 mmol/L or random ≥11.10 mmol/L) 	47/53 (88.7%) 	55/69 (79.7%) 	48/58 (82.8%) 	5.9 (-7.0, 18.9) 	-3.0 (-16.6, 10.5) 	
Potassium, high (>6.0 mmol/L) 	49/53 (92.5%) 	48/69 (69.6%) 	54/58 (93.1%) 	-0.7 (-10.3, 9.0) 	-23.5 (-36.2, -10.9) 	
Sodium, high (>155 mmol/L) 	45/53 (84.9%) 	56/66 (84.8%) 	50/58 (86.2%) 	-1.3 (-14.4, 11.8) 	-1.4 (-13.8, 11.0) 	
 	 	 	 	 	 	
Lipids 	 	 	 	 	 	
HDL Cholesterol, males, low (<0.776 mmol/L) 	44/53 (83.0%) 	54/71 (76.1%) 	51/59 (86.4%) 	-3.4 (-16.8, 9.9) 	-10.4 (-23.6, 2.8) 	
Triglycerides, high (>3.387 mmol/L) 	45/53 (84.9%) 	52/73 (71.2%) 	54/59 (91.5%) 	-6.6 (-18.6, 5.4) 	-20.3 (-32.9, -7.7) 	
 	 	 	 	 	 	
Liver biochemistry 	 	 	 	 	 	
Alanine Aminotransferase, high (>5x ULN Enzyme U/L) 	51/53 (96.2%) 	51/70 (72.9%) 	47/58 (81.0%) 	15.2 (3.9, 26.5) 	-8.2 (-22.7, 6.3) 	
Albumin, low (<25.0 g/L) 	44/53 (83.0%) 	52/67 (77.6%) 	50/59 (84.7%) 	-1.7 (-15.4, 11.9) 	-7.1 (-20.7, 6.4) 	
Alkaline Phosphatase, high (>2x ULN Enzyme U/L) 	47/52 (90.4%) 	53/69 (76.8%) 	49/58 (84.5%) 	5.9 (-6.4, 18.2) 	-7.7 (-21.3, 6.0) 	
Aspartate Aminotransferase, high (>5x ULN Enzyme U/L) 	49/53 (92.5%) 	54/71 (76.1%) 	55/58 (94.8%) 	-2.4 (-11.5, 6.7) 	-18.8 (-30.2, -7.3) 	

Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.] 	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]